Ulthera Appoints Greg Waller as CFO
Ulthera, a global commercial-stage medical device company, has named Greg Waller as chief financial officer (CFO), a newly created position. Waller’s 35 years of experience showcases a solid track record of strategic financial growth for both privately held and publically traded companies.
Most recently, Waller served as CFO of Universal Building Products, a manufacturer of concrete construction accessories. Prior to that, he held several leadership positions at Sybron Dental Specialties, a manufacturer and marketer of consumable dental products. During his 25-year tenure with Sybron, he was instrumental in the initial public offering (IPO) of the company and in more than 30 company acquisitions worldwide. He also played a pivotal role in supporting the growth of the company from 100 to more than 4,000 employees and from US$10m to more than US$750m in sales.
Waller currently serves as a board member and audit committee chairman for Endologix and as a board member for Sunshine Heart. Additionally, he previously served as board member and audit committee chairman for Alsius, Biolase, Cardiogenesis, Clarient and SenoRx, all publicly traded companies.